amg 451
mAbexperimental
Clinical trial activity
14 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
10
Phase 3
9
Phase 4
0
Earliest trial started May 31, 2022 (NCT05398445)
Timeline
Indications
Mechanism of action
TNFSF4 antagonist
Tumor necrosis factor receptor superfamily member 4 antagonist
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594567 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06438263 | Phase 1 | Aug 6, 2024 | Amgen |
| NCT06527404 | Phase 3 | Jul 18, 2024 | Amgen |
| NCT06376045 | Phase 2 | May 24, 2024 | Amgen |
| NCT06224192 | Phase 3 | Apr 2, 2024 | Amgen |
| NCT06268860 | Phase 1 | Feb 15, 2024 | Amgen |
| NCT06214481 | Phase 1 | Jan 23, 2024 | Amgen |
| NCT05899816 | Phase 3 | Jun 7, 2023 | Amgen |
| NCT05891119 | Early Phase 1 (Phase 1) | Jun 3, 2023 | Amgen |
| NCT05882877 | Phase 3 | May 31, 2023 | Amgen |
| NCT05704738 | Phase 3 | Apr 20, 2023 | Amgen |
| NCT05724199 | Phase 3 | Feb 21, 2023 | Amgen |
| NCT05633355 | Phase 3 | Dec 23, 2022 | Amgen |
| NCT05651711 | Phase 3 | Dec 14, 2022 | Amgen |
| NCT05398445 | Phase 3 | May 31, 2022 | Amgen |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 14 | 14 | 3 | 2022 |
1 organizations
Page 1 / 1